Status:
UNKNOWN
A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Lymph Node Metastasis
Hepatocellular Carcinoma
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Objectives: 1. To further validate the predictive efficacy of our established microRNA prediction model of HCC lymph node metastasis. 2. To establish a precise therapeutic mode of prophylactic radiat...
Detailed Description
First, screening out patients who underwent hepatic tumor resection and pathologically diagnosed as HCC . Then，performing the detection of miR-145, miR-31 and miR-92a by using the HCC lymph node meta...
Eligibility Criteria
Inclusion
- patients underwent liver tumor resection and pathological diagnosis of HCC in our hospital.
- The tumor samples of these HCC patients were detected by in situ hybridization with miR-145, miR-31 and miR-92a. We used the previously established HCC lymph node metastasis microRNA prediction model to determine the patients with high-risk lymph node metastasis and low-risk patients at high risk Patients were randomly assigned into treatment group and control group with informed consent.
- HCC patients were not receive other anti-cancer treatment.
- Blood routine examination was normal.
- Child-Pugh grade A, normal liver and kidney function in the normal range (including ALT or ASL within 2.5 times the normal), WBC\> 3 × 109 / L, Hb\> 90g / L, PLT\> 50 × 109 /
- HCC patients were not receive the history of upper abdominal radiotherapy.
- sign the informed consent.
- age 18-75 years old.
- KPS score 80-100 points.
Exclusion
- accepted other anti-cancer treatment.
- Patients was determined to be low-risk lymph node metastasis by the pre-established HCC lymph node metastasis microRNA prediction model.
- blood and liver and kidney dysfunction.
- can not control the infection.
- at the same time the merger of other malignant tumors.
- while using other experimental drugs or to participate in other clinical trials.
- serious heart, lung, kidney disease.
- pregnant or lactating women.
- serious nervous system disease, can not clearly tell the treatment
Key Trial Info
Start Date :
February 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03416803
Start Date
February 1 2018
End Date
June 30 2020
Last Update
February 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, China, 200032